Oncolytic virus immunotherapies for cancer
| Date | Round | Amount |
|---|---|---|
| Feb 2024 | Grant Helsinki biotech TILT Biotherapeutics received a $2M US Department of Defense grant for ovarian-cancer immunotherapy research. | $2M |
| Jan 2023 | Funding round Helsinki biotech TILT Biotherapeutics raised EUR12M (incl. EIC funding) led by Lifeline Ventures. | $13M |
| Jun 2022 | Funding round Helsinki biotech TILT Biotherapeutics raised EUR10M led by Lifeline Ventures with Tesi to advance its cancer immunotherapy trials. | $10.7M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.